Inter-patient variability in docetaxel pharmacokinetics: A review. Issue 7 (July 2015)

• Record Type: Journal Article
• Authors: Nieuweboer, Annemieke J.M.; de Morrée, Ellen S.; de Graan, Anne-Joy M.; Sparreboom, Alex; de Wit, Ronald; Mathijssen, Ron H.J.
• Is Part Of: Cancer treatment reviews. Volume 41:Issue 7(2015)
• Page Start: 605
• Page End: 613
• Publication Date: 2015-07
• Subjects: Docetaxel -- Pharmacokinetics -- Drug-transporters -- Drug–drug interactions -- Patient factors -- Environmental factors; Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2015.04.012
• Languages: English
• ISSNs: 0305-7372

Abstract

Graphical abstract: Highlights: There are drug–drug interactions with docetaxel that are of clinical importance. Liver impairment may reduce docetaxel clearance. Gender and hormonal status may be of importance in future dosing strategies for docetaxel. Interactions affecting uptake transporters potentially influence hepatic uptake of docetaxel. The role of pharmacogenetics in docetaxel pharmacokinetics is currently still limited. Abstract: Docetaxel is a frequently used chemotherapeutic agent in the treatment of solid cancers. Because of the large inter-individual variability (IIV) in the pharmacokinetics (PK) of docetaxel, it is challenging to determine the optimal dose in individual patients in order to achieve optimal efficacy and acceptable toxicity. Despite the established correlation between systemic docetaxel exposure and efficacy, the precise factors influencing docetaxel PK are not yet completely understood. This review article highlights currently known factors that influence docetaxel PK, and focusses on those that are clinically relevant. For example, liver impairment should be taken into account when calculating docetaxel dosages as this may decrease docetaxel clearance. In addition, drug–drug interactions may be of distinct clinical importance when using docetaxel. Particularly, drugs strongly inhibiting CYP3A4 such as ketoconazole should not be concurrently administered without dose modification, as they may decrease the clearance of docetaxel. Gender, castration status, and menopausal status might be of importance as potential factors influencing docetaxel PK. The role of pharmacogenetics in predicting docetaxel PK is still limited, since no polymorphisms of clinical importance have yet been established.